Innovative preclinical investigations for metabolic disorders & diseases

Enterosys is a CRO scientifically rooted in the gut and gut-peripheral organs axis

The gut-brain axis, which provides bi-directional communication between the gastrointestinal and central nervous systems, plays a fundamental role in the regulation of metabolism, including the regulation of appetite, glucose and lipid homeostasis, and gastrointestinal function.

Current research suggests a much broader role for gut-brain circuits in physiology and disease. Targeting these circuits has become a major focus in the development of new molecules for therapeutic or therapeutic purposes. However, our current knowledge of this biology is limited, largely because there are few scientific tools to provide a detailed mechanistic understanding of gut-brain communication.

Research on the gut-brain axis has historically focused on the study of individual components of this system, but the technologies and integrated approach offered by Enterosys now provide a better understanding of how signals from these components are orchestrated to regulate metabolism. Our innovative methods allow us to exploit new knowledge to explore new approaches for the treatment of metabolic diseases and disorders.

Metabolic disorders & diseases interacting with the gut and gut- peripheral organs axis

AGING

is usually associated with the development of a metabolic syndrome due to the disturbance of inter-organs communication.

HEPATIC FIBROSIS

corresponds to the formation of an abnormally large amount of scar tissue in the liver. Severe scarring of the liver can lead to cirrhosis, which causes various symptoms characteristic of liver disease.

METABOLIC SYNDROME

is a pathological condition in which the body’s metabolism is altered leading to the development of pathological conditions such as type 2 diabetes, obesity, cardiovascular disease, hepatic steatosis and stroke.

NAFLD

or Non-Alcoholic Fatty Liver Disease represents an excessive accumulation of lipids in hepatocytes not related to alcohol consumption. wo main entities can be distinguished: steatosis isolated or accompanied by minimal lobular inflammation (non-alcoholic fatty liver or NAFL) and non-alcoholic steatohepatitis (NASH).

NASH

or non-alcoholic steatohepatitis is defined by the presence of steatosis with lobular inflammation and ballooning of the hepatocytes. It corresponds to the aggressive form of the disease which favors the accumulation of fibrosis in the liver leading to cirrhosis and its associated complications.

OBESITY

is defined an excess of body weight with a body max index superior to 30kg/m2. Nowadays, near to one billion of people suffers from obesity.

OVERWEIGHT

is defined by a body max index between 25 and 29.9kg/m2. Approx. 40% of people in the world are in overweight.

TYPE 2 DIABETES

is a pathological state characterized by fasted and fed hyperglycemia, hyperinsulinemia, glucose intolerance and insulin-resistance.

At the cutting edge of preclinical studies in metabolic diseases

Enterosynes from various origins can target enteric neurons and regulate their activity to restore a physiological gut-brain axis communication.

Figure from Knauf C, Abot A, Wemelle E, Cani PD. Targeting the Enteric Nervous System to Treat Metabolic Disorders? “Enterosynes” as Therapeutic Gut Factors. Neuroendocrinology. 2020;110(1-2):139-146. doi: 10.1159/000500602. Epub 2019 Jul 2. PMID: 31280267.

Discover our preclinical models

Enterosys offers you a complete and innovative offer of preclinical protocols based on in vitro and in vivo efficacy tests.

Discover our approach

Our experience in R&D allows us to meet your objectives and offer you support for the design and development of new models, guided by our innovation management approach.

Discover our preclinical models

Enterosys offers you a complete and innovative offer of preclinical protocols based on in vitro and in vivo efficacy tests.

Discover our approach

Our experience in R&D allows us to meet your objectives and offer you support for the design and development of new models, guided by our innovation management approach.

Gut & gut-organs communication: major role in many disorders and diseases

NEURODEGENERATIVE DISEASES

GASTROINTESTINAL DISEASES

DERMATOLOGICAL DISEASES

Question about the contribution of Gut and Gut-organs axis to your preclinical studies and innovation portfolio ?

Our team of experts will be happy to answer all your questions and discuss with you to guide you in the design of an optimized protocol to meet your objectives and add value to your molecules with quick and concrete solutions.